Healthcare -
Biotechnology - NASDAQ - US
$ 14.31
-5.36 %
$ 273 M
Market Cap
-6.12
P/E
1. INTRINSIC VALUE
Balance Sheet
Structure Therapeutics Inc.
| Current Assets | 891 M |
| Cash & Short-Term Investments | 884 M |
| Receivables | 0 |
| Other Current Assets | 7.69 M |
| Non-Current Assets | 12.1 M |
| Long-Term Investments | 0 |
| PP&E | 7.01 M |
| Other Non-Current Assets | 5.11 M |
| Current Liabilities | 36 M |
| Accounts Payable | 8.02 M |
| Short-Term Debt | 1.7 M |
| Other Current Liabilities | 26.3 M |
| Non-Current Liabilities | 2.47 M |
| Long-Term Debt | 2.16 M |
| Other Non-Current Liabilities | 302 K |
EFFICIENCY
Earnings Waterfall
Structure Therapeutics Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 158 M |
| Operating Income | -158 M |
| Other Expenses | -35.7 M |
| Net Income | -123 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Structure Therapeutics Inc.
| Net Income | -123 M |
| Depreciation & Amortization | 992 K |
| Capital Expenditures | -1.29 M |
| Stock-Based Compensation | 18.8 M |
| Change in Working Capital | 2.96 M |
| Others | -17.2 M |
| Free Cash Flow | -118 M |
Wall Street Analysts Price Targets
Structure Therapeutics Inc.
Wall Street analysts predict an average 1-year price target for GPCR of $99.2 , with forecasts ranging from
a
low of
$86 to a high of $118 .
GPCR Lowest Price Target
Wall Street Target
86 USD
500.98%
GPCR Average Price Target
Wall Street Target
99.2 USD
593.57%
GPCR Highest Price Target
Wall Street Target
118 USD
724.60%
4. DIVIDEND
ANALYSIS
GPCR does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Structure Therapeutics Inc.
Sold
0-3 MONTHS
0 USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Structure Therapeutics CEO on latest GLP-1 developments
Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill.
youtube.com
- 3 weeks ago
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer a competitive edge.
seekingalpha.com
- 1 month ago
Why Structure Therapeutics Stock Was Stumbling This Week
The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (GPCR 0.16%), was a victim of a general rout in the segment.
fool.com
- 2 months ago
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.
globenewswire.com
- 2 months ago
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan has reset the valuation for Viking Therapeutics Inc. VKTX and Structure Therapeutics Inc. GPCR.
benzinga.com
- 3 months ago
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans
globenewswire.com
- 4 months ago
Structure CEO on the competitive landscape for oral GLP-1 drugs
Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.
youtube.com
- 4 months ago
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones
A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.
benzinga.com
- 5 months ago
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK.
globenewswire.com
- 5 months ago
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS clinical study evaluating GSBR-1290 in participants living with obesity, or overweight with a weight-related comorbidity.
globenewswire.com
- 5 months ago
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs).
globenewswire.com
- 5 months ago
Best Momentum Stocks to Buy for October 23rd
GPCR, RUSHA and NTRA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 23, 2024.
zacks.com
- 5 months ago
8. Profile
Summary
Structure Therapeutics Inc. GPCR
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 273 M
Dividend Yield
0.00%
Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Contact
611 Gateway Boulevard, South San Francisco, CA, 94080
https://structuretx.com
IPO
Date
Feb. 3, 2023
Employees
163
Officers
Mr. Bob Gatmaitan
Senior Vice President of People
Mr. Jun S. Yoon
Co- Founder, Chief Financial Officer & Secretary
Dr. Yingli Ma Ph.D.
Chief Technology Officer
Ms. Lani Ibarra
Senior Vice President of Clinical Development Operations
Dr. Xichen Lin Ph.D.
Chief Scientific Officer
Dr. Hui Lei Ph.D.
Senior Vice President of Chemistry
Dr. Raymond C. Stevens Ph.D.
Chief Executive Officer & Director
Dr. Fang Zhang Ph.D.
Executive Vice President & Head of Biology
Mr. Tony Peng
Senior Vice President of Legal
Dr. Xinglong Jiang Ph.D.
Senior Vice President of Preclinical Development